Latest news with #CIHR
National Post
23-05-2025
- Business
- National Post
Canada $5.79 Bn Legal Cannabis Market Share, Trends Analysis and Growth Forecasts, 2025-2030: New Educational Initiatives Propel Awareness, Rising Use of CBD for Anxiety, Pain, and Seizures
Article content Article content Article content DUBLIN — The 'Canada Legal Cannabis Market Size, Share, and Trends Analysis Report by Source (Marijuana, Hemp), Derivatives (CBD, THC), Cultivation, End-use (Medical, Recreational, Industrial), with Growth Forecasts, 2025-2030' report has been added to offering. Article content The Canada Legal Cannabis Market was valued at USD 3.25 Billion in 2024, and is projected to reach USD 5.79 Billion by 2030, rising at a CAGR of 12.00% Article content Growing awareness of the health benefits related to cannabis and CBD consumption for treating anxiety & seizures and reducing pain is projected to propel the market growth. The high demand for CBD for health and wellness purposes, attributed to its therapeutic properties, is a key driver in the market's growth. Article content Moreover, the rising number of clinical trials signifies the positive effects of utilizing cannabis for treating various medical conditions. For instance, in February 2024, researchers at the University of British Columbia introduced a first-of-its-kind clinical trial examining the potential of CBD as a treatment for bipolar depression. The trials were approved by Health Canada and funded by the Canadian Institutes of Health Research (CIHR) to investigate how CBD can help manage acute bipolar depression. Article content Moreover, medical professionals' increasing preference for cannabinoid-based formulations to treat numerous health conditions is another major factor supporting the country's market. Healthcare professionals' higher preference for CBG, CBN-derived products creates a positive influence on consumer minds, thereby boosting their adoption rate and popularity. For instance, in October 2021, Cronos Group Inc. launched its SPINACH FEELZ Chill Bliss 2:1 THC|CBG gummy that features THC and cultured CBG. Article content Some of the key players in the market are Canopy Growth Corporation, Charlotte's Web, Inc., Aurora Cannabis, Tilray Brands, The Cronos Group, Jazz Pharmaceuticals, Inc., Sundial Growers, and Maricann, Inc. These market players adopt key strategic initiatives to expand their business footprint and market position. For instance, in April 2023, Aurora Cannabis Inc. partnered with Strainprint and announced the launch of the tracking program through Strainprint App. The tracking program is designed for Aurora patients to keep track of their medical cannabis journey. Article content Furthermore, the rise in awareness regarding cannabis and its potential use in various industries and the introduction of educational programs boost the market growth. For instance, in July 2022, Tilray Brands launched a cannabis education platform, WeCare-Medical Cannabis. The platform is dedicated to educating patients and healthcare practitioners about medical cannabis. Article content Based on source, the marijuana segment dominated the market in 2025 and is anticipated to witness the fastest growth over the forecast period owing to the growing adoption of marijuana-based products Based on derivatives, the CBD segment held the largest market share in 2025, owing to the awareness regarding CBD's effectiveness in treating various medical conditions Based on cultivation, the indoor segment held the largest market share in 2025 due to the incorporation of artificial intelligence (AI) in cannabis cultivation, rising investments, and favorable government initiatives Based on end use, the recreational segment dominated the market in 2025 and is anticipated to grow at the fastest CAGR over the forecast period due to the growing consumption of cannabis in the form of vapes, foods, and beverages Article content Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments. Competitive Landscape: Explore the market presence of key players. Future Trends: Discover the pivotal trends and drivers shaping the future of the market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions. Article content Chapter 1. Methodology and Scope Article content Chapter 2. Executive Summary Article content 2.1. Market Outlook Article content 2.2. Segment Outlook Article content 2.2.1. Source outlook Article content 2.2.2. Derivatives outlook Article content 2.2.3. Cultivation outlook Article content 2.2.4. End Use outlook Article content 2.3. Competitive Insights Article content Chapter 3. Canada Legal Cannabis Market Variables, Trends & Scope Article content 3.1. Market Lineage Outlook Article content 3.1.1. Parent market outlook Article content 3.1.2. Ancillary market outlook Article content 3.2. Market Dynamics Article content 3.2.1. Market driver analysis Article content 3.2.2. Market restraint analysis Article content 3.3. Canada Legal Cannabis: Market Analysis Tools Article content 3.3.1. Industry Analysis – Porter's Article content 3.3.2. PESTLE Analysis Article content 3.4. Regulatory Framework Article content Chapter 4. Canada Legal Cannabis Market Segment Analysis, by Source, 2018-2030 (USD Million) Article content 4.1. Definition and Scope Article content 4.2. Product Market Share Analysis, 2024 & 2030 Article content 4.3. Segment Dashboard Article content 4.4. Canada Legal Cannabis market, by Source, 2018 to 2030 Article content 4.5. Marijuana Article content 4.5.1. Marijuana market estimates and forecasts, 2018 to 2030 (USD Million) Article content 4.5.2. Flowers Article content 4.5.3. Oil and Tinctures Article content 4.6. Hemp Article content 4.6.1. Hemp market estimates and forecasts, 2018 to 2030 (USD Million) Article content 4.6.2. Hemp Oil Article content 4.6.3. Industrial Hemp Article content Chapter 5. Canada Legal Cannabis Market Segment Analysis, by Derivatives, 2018-2030 (USD Million) Article content 5.1. Definition and Scope Article content 5.2. Derivatives Market Share Analysis, 2024 & 2030 Article content 5.3. Segment Dashboard Article content 5.4. Canada Legal Cannabis market, by Derivatives, 2018 to 2030 Article content 5.5. CBD Article content 5.6. THC Article content 5.7. Other derivatives Article content Chapter 6. Canada Legal Cannabis Market Segment Analysis, by Cultivation, 2018-2030 (USD Million) Article content 6.1. Definition and Scope Article content 6.2. Cultivation Market Share Analysis, 2024 & 2030 Article content 6.3. Segment Dashboard Article content 6.4. Canada Legal Cannabis market, by Cultivation, 2018 to 2030 Article content 6.5. Indoor Cultivation Article content 6.6. Greenhouse Cultivation Article content 6.7. Outdoor Cultivation Article content Chapter 7. Canada Legal Cannabis Market Segment Analysis, by End Use, 2018-2030 (USD Million) Article content 7.1. Definition and Scope Article content 7.2. End Use Market Share Analysis, 2024 & 2030 Article content 7.3. Segment Dashboard Article content 7.4. Global Canada Legal Cannabis Market, by End Use, 2018 to 2030 Article content 7.5. Medical Use Article content 7.5.1. Medical Use Market Revenue Estimates and Forecasts, 2018-2030 (USD Million) Article content 7.5.2. Cancer Article content 7.5.3. Chronic Pain Article content 7.5.4. Depression and Anxiety Article content 7.5.5. Arthritis Article content 7.5.6. Diabetes Article content 7.5.7. Glaucoma Article content 7.5.8. Migraine Article content 7.5.9. Epilepsy Article content 7.5.10. Multiple Sclerosis Article content 7.5.11. AIDS Article content 7.5.12. Amyotrophic Lateral Sclerosis Article content 7.5.13. Alzheimer's Article content 7.5.14. Post Traumatic Stress Disorder (PTSD) Article content 7.5.15. Parkinson's Article content 7.5.16. Tourette's Article content 7.5.17. Others Article content 7.6. Recreational Use Article content 7.7. Industrial Use Article content Chapter 8. Competitive Landscape Article content 8.1. Recent Developments & Impact Analysis, by Key Market Participants Article content 8.2. Company Categorization Article content 8.3. Company Profiles Article content Canopy Growth Corporation Charlotte's Web, Inc. Aurora Cannabis Inc. Tilray Brands The Cronos Group Jazz Pharmaceuticals, Inc. Organigram Holding, Inc. Maricann, Inc. Isodiol International, Inc Sundial Growers Article content is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Article content Article content Article content Article content Article content Contacts Article content Article content Article content
Yahoo
22-05-2025
- Business
- Yahoo
Canada Legal Cannabis Industry Report 2025-2030: Industry Leaders like Canopy Growth and Tilray Brands Steer Market Expansion
Canada's legal cannabis market, valued at USD 3.25 Billion in 2024, is projected to reach USD 5.79 Billion by 2030, growing at a 12% CAGR. Key drivers include health benefits awareness, increasing clinical trials, and product innovation. . Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Canada Legal Cannabis Market Size, Share, and Trends Analysis Report by Source (Marijuana, Hemp), Derivatives (CBD, THC), Cultivation, End-use (Medical, Recreational, Industrial), with Growth Forecasts, 2025-2030" report has been added to Canada Legal Cannabis Market was valued at USD 3.25 Billion in 2024, and is projected to reach USD 5.79 Billion by 2030, rising at a CAGR of 12.00% Growing awareness of the health benefits related to cannabis and CBD consumption for treating anxiety & seizures and reducing pain is projected to propel the market growth. The high demand for CBD for health and wellness purposes, attributed to its therapeutic properties, is a key driver in the market's the rising number of clinical trials signifies the positive effects of utilizing cannabis for treating various medical conditions. For instance, in February 2024, researchers at the University of British Columbia introduced a first-of-its-kind clinical trial examining the potential of CBD as a treatment for bipolar depression. The trials were approved by Health Canada and funded by the Canadian Institutes of Health Research (CIHR) to investigate how CBD can help manage acute bipolar medical professionals' increasing preference for cannabinoid-based formulations to treat numerous health conditions is another major factor supporting the country's market. Healthcare professionals' higher preference for CBG, CBN-derived products creates a positive influence on consumer minds, thereby boosting their adoption rate and popularity. For instance, in October 2021, Cronos Group Inc. launched its SPINACH FEELZ Chill Bliss 2:1 THC|CBG gummy that features THC and cultured of the key players in the market are Canopy Growth Corporation, Charlotte's Web, Inc., Aurora Cannabis, Tilray Brands, The Cronos Group, Jazz Pharmaceuticals, Inc., Sundial Growers, and Maricann, Inc. These market players adopt key strategic initiatives to expand their business footprint and market position. For instance, in April 2023, Aurora Cannabis Inc. partnered with Strainprint and announced the launch of the tracking program through Strainprint App. The tracking program is designed for Aurora patients to keep track of their medical cannabis the rise in awareness regarding cannabis and its potential use in various industries and the introduction of educational programs boost the market growth. For instance, in July 2022, Tilray Brands launched a cannabis education platform, WeCare-Medical Cannabis. The platform is dedicated to educating patients and healthcare practitioners about medical Legal Cannabis Market Report Highlights Based on source, the marijuana segment dominated the market in 2025 and is anticipated to witness the fastest growth over the forecast period owing to the growing adoption of marijuana-based products Based on derivatives, the CBD segment held the largest market share in 2025, owing to the awareness regarding CBD's effectiveness in treating various medical conditions Based on cultivation, the indoor segment held the largest market share in 2025 due to the incorporation of artificial intelligence (AI) in cannabis cultivation, rising investments, and favorable government initiatives Based on end use, the recreational segment dominated the market in 2025 and is anticipated to grow at the fastest CAGR over the forecast period due to the growing consumption of cannabis in the form of vapes, foods, and beverages Why Should You Buy This Report? Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments. Competitive Landscape: Explore the market presence of key players. Future Trends: Discover the pivotal trends and drivers shaping the future of the market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions. Key Topics Covered: Chapter 1. Methodology and ScopeChapter 2. Executive Summary2.1. Market Outlook2.2. Segment Outlook2.2.1. Source outlook2.2.2. Derivatives outlook2.2.3. Cultivation outlook2.2.4. End Use outlook2.3. Competitive InsightsChapter 3. Canada Legal Cannabis Market Variables, Trends & Scope3.1. Market Lineage Outlook3.1.1. Parent market outlook3.1.2. Ancillary market outlook3.2. Market Dynamics3.2.1. Market driver analysis3.2.2. Market restraint analysis3.3. Canada Legal Cannabis: Market Analysis Tools3.3.1. Industry Analysis - Porter's3.3.2. PESTLE Analysis3.4. Regulatory FrameworkChapter 4. Canada Legal Cannabis Market Segment Analysis, by Source, 2018-2030 (USD Million)4.1. Definition and Scope4.2. Product Market Share Analysis, 2024 & 20304.3. Segment Dashboard4.4. Canada Legal Cannabis market, by Source, 2018 to 20304.5. Marijuana4.5.1. Marijuana market estimates and forecasts, 2018 to 2030 (USD Million)4.5.2. Flowers4.5.3. Oil and Tinctures4.6. Hemp4.6.1. Hemp market estimates and forecasts, 2018 to 2030 (USD Million)4.6.2. Hemp Oil4.6.3. Industrial HempChapter 5. Canada Legal Cannabis Market Segment Analysis, by Derivatives, 2018-2030 (USD Million)5.1. Definition and Scope5.2. Derivatives Market Share Analysis, 2024 & 20305.3. Segment Dashboard5.4. Canada Legal Cannabis market, by Derivatives, 2018 to 20305.5. CBD5.6. THC5.7. Other derivativesChapter 6. Canada Legal Cannabis Market Segment Analysis, by Cultivation, 2018-2030 (USD Million)6.1. Definition and Scope6.2. Cultivation Market Share Analysis, 2024 & 20306.3. Segment Dashboard6.4. Canada Legal Cannabis market, by Cultivation, 2018 to 20306.5. Indoor Cultivation6.6. Greenhouse Cultivation6.7. Outdoor CultivationChapter 7. Canada Legal Cannabis Market Segment Analysis, by End Use, 2018-2030 (USD Million)7.1. Definition and Scope7.2. End Use Market Share Analysis, 2024 & 20307.3. Segment Dashboard7.4. Global Canada Legal Cannabis Market, by End Use, 2018 to 20307.5. Medical Use7.5.1. Medical Use Market Revenue Estimates and Forecasts, 2018-2030 (USD Million)7.5.2. Cancer7.5.3. Chronic Pain7.5.4. Depression and Anxiety7.5.5. Arthritis7.5.6. Diabetes7.5.7. Glaucoma7.5.8. Migraine7.5.9. Epilepsy7.5.10. Multiple Sclerosis7.5.11. AIDS7.5.12. Amyotrophic Lateral Sclerosis7.5.13. Alzheimer's7.5.14. Post Traumatic Stress Disorder (PTSD)7.5.15. Parkinson's7.5.16. Tourette's7.5.17. Others7.6. Recreational Use7.7. Industrial UseChapter 8. Competitive Landscape8.1. Recent Developments & Impact Analysis, by Key Market Participants8.2. Company Categorization8.3. Company Profiles Canopy Growth Corporation Charlotte's Web, Inc. Aurora Cannabis Inc. Tilray Brands The Cronos Group Jazz Pharmaceuticals, Inc. Organigram Holding, Inc. Maricann, Inc. Isodiol International, Inc Sundial Growers For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
CBC
10-05-2025
- Health
- CBC
Why doctors and researchers say Canada needs to change course on women's health studies
This story is part of CBC Health's Second Opinion, a weekly analysis of health and medical science news emailed to subscribers on Saturday mornings. If you haven't subscribed yet, you can do that by clicking here. Despite a rule that requires sex and gender to be considered when funding medical research in Canada, new research shows the number of grants for women's health studies hasn't budged in five years, something doctors say has serious implications for their patients. The Canadian Institutes of Health Research (CIHR) has mandated the inclusion of sex and gender as criteria for awarding grants since 2010. Despite that, a group of researchers found in 2023 that less than six per cent of Canadian health research funding went to women's health. Now, their new study is also analyzing how narrow the field of women's health research is. While women's health is currently more focused on areas like pregnancy and breast and gynecological cancers, doctors and researchers say they want to see the field broaden to include other conditions, like migraine headaches, chronic pelvic pain and fibromyalgia, which studies show are more common among women, but garner less research funding. Dr. Tania Di Renna, the medical director of the Toronto Academic Pain Medicine Institute, who works as an anesthesiologist at Women's College Hospital in Toronto, says she promises her patients she'll study their conditions with the goal of finding the source of their chronic pelvic pain, something she says is important, because traditionally, health-care professionals have brushed off women's pain. Di Renna says that's partly because before 1993, women were rarely included in clinical trials due to concerns that pregnancy could interrupt the study, or that trials could pose potential dangers to the fetus. Di Renna also notes that medical researchers would even leave female animals out of studies. Lack of clinical trials for women These concerns trace back to the use of thalidomide in the late 1950s and early 1960s. The morning sickness drug had debilitating effects on babies in multiple countries, including Canada. Di Renna sees this lack of female subjects in clinical trials play out when it comes time to prescribe medications for her patients suffering with chronic pelvic pain. She says when she prescribes medications, her patients often tell her about certain side effects they experience. "Women tell me that, 'I can't take this drug. It makes me nauseous. It makes me gain weight. It makes me sedated.' [Women] have so many things going against us already, and now even the medications that are there to treat you are going against you." Due to policy and social changes in the 1990s, research into women's health has increased, but Di Renna says there's more work to be done. For example, the way women respond to opioid pain medications differs from men, but why this is remains unclear, Di Renna said. In 2022, a review of studies on sex-related differences in response to medications concluded that opioids seemed to produce better pain relief in women, especially when administered for a few days. But responses also seemed inconsistent, with factors like the type of treatment, menopausal status and characteristics of the pain all contributing. This kind of uncertainty and lack of research means physicians may not be able to find the cause of chronic pain for female patients. In those cases, Di Renna says "we really have to move on and focus on how you can live with a good quality of life." Other physicians say this may include better medications to treat pain, or other methods of pain management such as physio, meditation, or even heating pads for cramps. WATCH | All about menopause and perimenopause: Everything you need to know about menopause (and perimenopause) 2 years ago Duration 9:40 Low funding, narrow focus Migraines are an example of a condition that research shows impacts more women than men. The prevalence of migraines is the same for girls and boys before puberty, according to Dr. Peter Goadsby, a neurologist in headache disorders at King's College Hospital in London. But doctors have observed that after the first period, women experience migraines three times more frequently than men, and that migraines typically decline after menopause. Despite this, the authors of a new Canadian preprint found a single female-specific grant application to CIHR for the study of how migraines affect women over 13 years. Overall, Liisa Galea and her team found female-specific research funding has not changed since 2020, staying at about seven per cent. The study, which hasn't yet been peer-reviewed, also suggests that the research conducted in women's health largely focuses on breast and gynecologic cancers or pregnancy. They argue the field of women's health research should be much broader. Galea, who holds the Treliving Family Chair in Women's Mental Health at Toronto's Centre for Addiction and Mental Health, led the new analysis, as well as a similar submission to the House of Commons health committee in 2024. WATCH | Why heart disease is underdiagnosed in many women: What women need to know about heart disease 3 years ago Duration 8:37 A woman in Canada dies of heart disease every 22 minutes, and most don't have to. CBC's Ioanna Roumeliotis explores why so many women are underdiagnosed and what they can do to protect themselves. She says she experienced pushback herself when she applied for CIHR grants to examine the influence of pregnancy history on the risk of Alzheimer's disease. Galea says she was told that she needed to add biological males to her study. "Unless you're Arnold Schwarzenegger in a particular movie, you can't get a male pregnant. But that was a criticism." To Galea, the answer is that medical researchers should be "allowed to just study females." Millions of migraines, little investment How and why hormones affect migraines is not fully understood, but scientists say migraine attacks related to menstruation tend to be longer. Goadsby, the neurologist, says this suggests fluctuations in hormones like estrogen and progesterone play a role. Jerilynn Prior, who researches women's reproductive health at the Centre for Menstrual Cycle and Ovulation Research at the University of British Columbia, says that when it comes to migraines, estrogen itself may not cause the condition, but changes in hormone levels can influence how pain is interpreted. Prior has run several randomized control trials showing that progesterone capsules improve deep sleep in certain perimenopausal women. "I think of estrogen as a brain-activating hormone," Prior said. "It is also associated with inflammation, which is associated with pain. I think of progesterone as estrogen's partner hormone, and it's associated with brain calming." She notes that pain is a very personal sensation and that a whole host of non-medical factors can make it better or worse, including social stress and environment. For Goadsby, the fact that we know so little about female migraine pain indicates that our understanding of women's health is seriously lacking. "How did we get to the point where there are hundreds of millions of females with migraines in the world and we don't understand the biology terribly well? We haven't invested in it," he said. "It's a glaring area that needs more work."
